Related Experiment Videos
Prevention and management of chronic heart failure with electrical therapy
1Cardiac Electrophysiology Section, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. e-engelstein@northwestern.edu
Insights
Electrical therapies like implantable cardioverter defibrillators (ICDs) and catheter ablation are crucial for preventing sudden cardiac death in heart failure patients. Risk stratification remains key for optimizing treatment outcomes.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Sudden cardiac death (SCD) accounts for over 40% of heart failure mortality.
- Preventing life-threatening arrhythmias is a primary management goal in heart failure.
- Implantable cardioverter defibrillators (ICDs) show superiority over antiarrhythmic drugs for SCD prevention in reduced ejection fraction.
Purpose of the Study:
- To review the role of electrical therapies in managing heart failure and preventing sudden cardiac death.
- To discuss the effectiveness of ICDs and catheter ablation based on cardiomyopathy etiology.
- To highlight advancements in pacing and ablation for heart failure patients.
Main Methods:
- Review of randomized clinical trials on electrical therapies for heart failure.
- Analysis of outcomes data for ICD therapy in ischemic versus non-ischemic cardiomyopathy.
- Evaluation of catheter ablation and cardiac resynchronization therapy (CRT) in heart failure.
Main Results:
- ICDs improve survival in ischemic cardiomyopathy but data for non-ischemic cardiomyopathy are less conclusive.
- Catheter ablation effectively treats tachycardia-mediated cardiomyopathy and reduces ventricular tachyarrhythmias.
- Cardiac resynchronization therapy (CRT) via biventricular pacing offers significant symptomatic and hemodynamic benefits.
Conclusions:
- Electrical therapies, including ICDs and catheter ablation, are vital for managing heart failure and reducing SCD.
- Risk stratification for arrhythmic death is a critical challenge in heart failure management.
- Advancements in catheter ablation and pacing significantly improve outcomes for heart failure patients.
Abstract:
Sudden cardiac death is responsible for >40% of patients with heart failure losing their lives. Thus, the prevention of life-threatening cardiac arrhythmias is a major goal in the management of heart failure. In several randomized clinical trials, electrical therapy with the implantable cardioverter defibrillator (ICD) has proved superior to medical antiarrhythmic therapy in both the secondary and primary prevention of sudden cardiac death in patients with reduced left ventricular function. In addition to the severity of left ventricular dysfunction, the etiology of the cardiomyopathy appears to be a determinant in the benefit derived from this form of electrical therapy. Whereas patients with ischemic cardiomyopathy clearly show improved survival with ICD therapy, outcome data in patients with nonischemic cardiomyopathy are less convincing. The major challenge lies in the risk stratification of patients with heart failure for arrhythmic death. Catheter ablation is another form of electrical therapy that can help in the treatment of patients with heart failure. In patients with a tachycardia-mediated cardiomyopathy because of drug-refractory atrial fibrillation with rapid ventricular response, catheter ablation of the atrioventricular node and pacemaker implantation can effectively restore a physiologic heart rate, often with dramatic regression of left ventricular dysfunction. In patients with frequent ICD therapies because of frequent recurrences of ventricular tachyarrhythmias, catheter ablation of ventricular tachycardia can be an effective adjunctive therapy. New catheter ablation techniques and new atrial pacing algorithms can also significantly reduce the atrial fibrillation burden in patients with heart failure who are particularly susceptible to decompensation because of atrial fibrillation. Pacing for hemodynamic benefit in heart failure has evolved from dual-chamber pacing modes with optimized atrioventricular delay to biventricular pacing resulting in cardiac resynchronization. This new treatment modality for advanced heart failure has been shown to result in significant symptomatic and hemodynamic improvement.